Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Following Pfizer’s proposed move for Seagen, Ben Hargreaves tracked how the ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Companies from these countries collectively account for 19 out of 28 assets worldwide. South Korea and China are leading in ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment. The research, which was funded by the blood ...

Contract research, development and manufacturing organisation (CRDMO) WuXi XDC Cayman has signed a memorandum of ...

According to preclinical results published today in Nature Cancer, the new approach combined the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid ...